




	1	N I IIE	UNITED SI	A I ES DESIGN	ATED/ELECTED OFFICE			
Interna	ational .	Applica	tion No.	:	PCT/EP2003/007068			
Interna	ational l	Filing E	Date	:	July 2, 2003			
Priorit	y Date(	s) Clair	ned	:	July 2, 2002			
Applic	ant(s) (	DO/EC	/US)	:	Frank MAYER et al.			
Title:	Citle: BACTERIAL CELL DIGESTION							
INFO	INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§ 1.56, 1.97 and 1.98							
P.O. B	issione lox 145 ndria, V	0	3-1450					
Sir:	r							
and 1.	This information disclosure statement is made in accordance with 37 C.F.R. §§ $1.56, 1.97$ and $1.98$ as follows:							
<u>Timin</u>	ming and Fees							
$\boxtimes$			R. § 1.97(b), tement is filed		ment is required for filing this information			
			three months § 1.53(d);	of the filing date	e of a national application other than a CPA			
			three months ation; OR	of the actual i	filing date of the national phase of a PCT			
	$\boxtimes$	before RCE)		a first substant	ive office action (including after filing of an			
					disclosure statement is filed after the periods the mailing date of:			
			a final rejecti	on under 37 C.I	F.R. 1.113;			
			termination o	of prosecution,	e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2);			

		is acco	ompanied by:
			the statement as specified in 37 C.F.R. § 1.97(e) set out below; OR
			a check covering the fee of \$180.00 under 37 C.F.R. § 1.17(p).
			R. $\S$ 1.97(d), this information disclosure statement is filed after the mailing lowing actions which have not been withdrawn:
			a final action under 37 C.F.R. § 1.113;
			termination of prosecution, e.g. Ex Parte Quayle, M.P.E.P $\S$ 609(B)(2); OR
			a notice of allowance under 37 C.F.R. § 1.311;
	AND i	s filed	on or before payment of the issue fee; AND is accompanied by:
			the statement as specified in 37 C.F.R. § 1.97(e) as set forth below, and the fee of \$180.00 under 37 C.F.R. § 1.17(p).
Staten	nents Ur	nder 37	C.F.R. 1.97(e)
			Each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application having a mailing date not more than three months prior to the filing date of this information disclosure statement; or
			No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the undersigned attorney after making reasonable inquiry, no item of information contained in this information disclosure statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing date of the information disclosure statement.
Cited	Materia	<u>ls</u>	
		ancest	s of materials listed but not attached were cited in benefit (35 U.S.C. § 120) or application Serial No, on Form 892 by the Examiner and/or Form by the applicant; see 37 C.F.R. § 1.98(d).
	$\boxtimes$		s of materials listed but not attached were cited in an international search dated March 1, 2004.
		Copies	s of the materials listed are attached (except for the foregoing).
			2

Non-English	Language References
$\boxtimes$	An English-language search report or equivalent paper from a foreign patent office is provided indicating the relevance of the cited reference(s).
	$\boldsymbol{A}$ foreign-language search report from a foreign patent office is provided, and pertinent parts are translated substantively below:
	X = document of particular relevance when it is taken alone Y = document of particular relevance when it is combined with another such document A = document defining the general state of the art
	O = non-written disclosure
	P = intercalated document T = document cited to understand the theory or principle underlying the
	invention
	E = patent document which has the benefit of a date earlier than the filing date and which was published only on or after this filing date
	D = cited in the application
	L = cited for another reason
	& = publication of member of same patent family
	Translation of other relevant information on foreign search report
	[insert necessary translation here]
Other Inform	ation
Payment of F	ees Due (If Any):
A che	ck for \$ covering the fee identified above is attached.

Please charge to Deposit Account No. 13-3402 \$ for the fee identified above.



 $\boxtimes$ The Commissioner is hereby authorized to charge or credit any overpayment to Deposit Account #13-3402, two copies of this paper are attached for this purpose.

Respectfully submitted,

y J. Zelano, Reg. No. 27

Attorneyt for Applicants

MILLEN, WHITE, ZELANO & BRANIGAN, P.C. Arlington Courthouse Plaza I 2200 Clarendon Blvd. Suite 1400

Arlington, Virginia 22201 Telephone: (703) 243-6333 Facsimile: (703) 243-6410

Attorney Docket No.: DREISS-2

Date: January 3, 2005

AJZ/ssr:aap

K:\Dreiss\2\Information Disclosure Statement.doc

Please type a plus sign (+) inside this box\_\_\_\_ ugh 10/31/2002. OMB 0851-0031

		Under the Paperwoo	rk Redu	Act of 1995, no persons	are required to respond to a collection	of information unless it contains a valid OMB control	number
1	Substitute	for form 1449A/PTC	)			Complete if Known	1341
ı					Application Number	Pling assigned on 10 0 2	JAN MID
ı	INFO	RMATION	DIS	CLOSURE	Filing Date	January 3, 2005	
ı	STAT	EMENT B	Y A	PPLICANT	First Named Inventor	Frank MAYER et al.	
ı					Group Art Unit	Unassigned	
ı		(use as many she	ets as	necessary)	Examiner Name	Unassigned	
┖	Sheet	1	of	2	Attorney Docket Number	DREISS-2	_

U.S. PATENT DOCUMENTS							
		U.S. Patent Doo	ument		Date of Publication of Cited Documen		
Examiner Initials *	Cite No.1	Number	Kind Code <sup>2</sup> (if known)	Name of Patentee or Applicant of Cited Document	MM-DD-YYYY		
			1 1				

		Foreign Patent Docu		ment		Date of Publication of	Pages, Columns, Lines, Where Relevant	
Examiner Initials*	Cite No.1	Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	T°
***************************************					Fraunhofer Ges	January 11, 200		
	1	DE	19929465		Forschung	January 11 200	>	
								_
				-			<b></b>	
		_					-	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST3.) For Japanese patent documents, the indication of the year of the reign of the Emperor must procede the serial number of the patent document. <sup>3</sup> Kind of document by the appropriate symbols as indicated on the document under VIPO Standard ST. 16 Possible. <sup>3</sup> Applicant is to place a check mark here if English language Translation is attached. Number refers to English language corresponding family member.

Burden Hour Statement. This form is astimated to take 2.0 Nours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of immy own are required to complete this term should be sent for the Chief Information Officer. US. Patient and Trademark of the Chief. Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patients, P.O. Box 1450, Alexandria, Va. 20231-1450.





Approved for use through 10/31/2002 OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE.

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE.

		Older the Tepan	CKICOL	COOT PCC OF 1000, NO pC 301 E	raic required to respond to a contection of	THE TENSOR OF THE TENSOR TO THE TENSOR THE T			
1	Substitute f	for form 1449A/PT	0		Complete if Known				
	INITO		-	OL COLUDE	Application Number	Unassigned			
				CLOSURE	Filing Date	January 3, 2005			
	STAT	EMENT B	YA	PPLICANT	First Named Inventor	Frank MAYER et al.			
					Group Art Unit	Unassigned			
	(	use as many sh	eets as	necessary)	Examiner Name	Unassigned			
₹	Sheet	2	of	2	Attorney Docket Number	DREISS-2			

		NON PATENT LITERATURE DOCUMENTS	
xaminer Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T2
	2	CONC. H. et.al.: "Crystal structure of intact elongation factor EF-Tu from Escherichia coll in GDP conformation at 2.05 A resolution" JOHANNAL OE MOI ECULAR BIOLOGY 22 NANUARY 1999 UNITED KINGDOM, vol. 285, no. 3, pages 1245–1255, XPUUZZ70506—	
	3	HEFFRON S.E.ET.Al.: "Structure of an EF-Tu complex with a thiazolyl peptide antibiotic determined at 2.35 A resolution: atomic basis for GF2270A inhibition of EF-Tu." BIOCHEMISTRY, UNITED STATES 11 January 2000, vol. 39, no. 4, pages 37.45, XPC01172470	
	4	HOGG T ET AL.: "Inhibition, mechanisms of antibiotics targeting elongation factor Tu." CURRENT PROTEIN & PEPTIDE SCIENCE: NETHERLANDS FEB 2002, vol. 3, no. 1, February 2002 pages 121-131, XP002270310.	
_			
			-

Examiner Signature	/Nancy Vogel/	Date Considered	09/12/2008
Congridatoro			00/12/2000

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

Burdan Hour Statement. This form is estimated to take 2.0 hours to complete. Time will very depending upon the needs of the individual case. Any comments on the amount of time you are resulted to complete this form should be seen to the Chief Immaster Officer. Very Hours of the Chief Immaster of Chief. Very Hours of the Chief. See All Chief. See All